These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38405208)

  • 1. High-dose alectinib for
    Dziadziuszko R; Peled N; Mok T; Peters S; Aix SP; Alatorre-Alexander J; Vicuna BD; Maclennan M; Bhagawati-Prasad V; Shagan SM; Schleifman E; Ruf T; Mathisen MS; Gadgeel SM
    Contemp Oncol (Pozn); 2023; 27(4):217-223. PubMed ID: 38405208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial.
    Felip E; Smit EF; Molina-Vila MA; Dafni U; Massuti B; Berghmans T; de Marinis F; Passiglia F; Dingemans AC; Cobo M; Viteri S; Britschgi C; Cuffe S; Provencio M; Merkelbach-Bruse S; Andriakopoulou C; Kammler R; Ruepp B; Roschitzki-Voser H; Peters S; Wolf J; Stahel R;
    Lung Cancer; 2022 Oct; 172():94-99. PubMed ID: 36030612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET).
    Takeuchi S; Yanagitani N; Seto T; Hattori Y; Ohashi K; Morise M; Matsumoto S; Yoh K; Goto K; Nishio M; Takahara S; Kawakami T; Imai Y; Yoshimura K; Tanimoto A; Nishiyama A; Murayama T; Yano S
    Transl Lung Cancer Res; 2021 Jan; 10(1):314-325. PubMed ID: 33569315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.
    Lin JJ; Kennedy E; Sequist LV; Brastianos PK; Goodwin KE; Stevens S; Wanat AC; Stober LL; Digumarthy SR; Engelman JA; Shaw AT; Gainor JF
    J Thorac Oncol; 2016 Nov; 11(11):2027-2032. PubMed ID: 27544060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Nie T; Syed YY
    Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
    Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
    Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of on-therapy ctDNA monitoring in a patient with
    Yeung V; Kim C; Kiedrowski LA; Liu SV; Reuss JE
    Transl Lung Cancer Res; 2022 Jan; 11(1):111-116. PubMed ID: 35242632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
    Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort.
    Dziadziuszko R; Mok T; Peters S; Han JY; Alatorre-Alexander J; Leighl N; Sriuranpong V; Pérol M; de Castro Junior G; Nadal E; de Marinis F; Frontera OA; Tan DSW; Lee DH; Kim HR; Yan M; Riehl T; Schleifman E; Paul SM; Mocci S; Patel R; Assaf ZJ; Shames DS; Mathisen MS; Gadgeel SM
    J Thorac Oncol; 2021 Dec; 16(12):2040-2050. PubMed ID: 34311110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.
    Takeuchi S; Murayama T; Yoshimura K; Kawakami T; Takahara S; Imai Y; Kuribayashi Y; Nagase K; Goto K; Nishio M; Hasegawa Y; Satouchi M; Kiura K; Seto T; Yano S
    J Med Invest; 2017; 64(3.4):317-320. PubMed ID: 28955006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of selpercatinib in Chinese patients with advanced
    Lu S; Cheng Y; Huang D; Sun Y; Wu L; Zhou C; Guo Y; Shao J; Zhang W; Zhou J
    Ther Adv Med Oncol; 2022; 14():17588359221105020. PubMed ID: 35923928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
    Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.